#Healthcare #HealthcareInnovation #DigitalHealth #Pharma #PharmaIndia #GLP1 #Semaglutide #Diabetes #DiabetesCare #Obesity #MedTech #HealthTech #IndianHealthcare #Innovation #FutureOfHealthcare To view or add a comment, sign in A debate over the adoption of GLP-1 weight-loss drugs in India has intensified after Biocon Executive Chairperson Kiran Mazumdar-Shaw cautioned against their widespread use among healthy individuals, responding to Zerodha Founder and CEO Nithin Kamath's observations on weaker-than-expected demand for generic versions of the medicines
Within this framework, potatoes can feature alongside diverse carbohydrate sources
Even moderate weight loss can improve blood pressure, cholesterol levels, and insulin sensitivity
But last August, a US judge dismissed all the cases in federal court after finding that expert witnesses lacked scientific evidence for their claims
In rare cases, serious side effects like pancreatitis, gallbladder issues, or thyroid tumors may arise
Semaglutide, when added to diet and exercise, resulted in 15 to 20% weight loss, but it also comes with potential risks and should be obtained through proper medical channels
